TIME MAY 3, 2019
08:30-10:00 ACUTE MYELOID LEUKEMIA
Scientific Chair: Gert Ossenkoppele (VU University Medical Center Amsterdam, The Netherlands)
AML Treatment Beyond 3+7: Hartmut Dohner (University Hospital,Ulm, DE)
The Emerging Role of MRD in AML: Gert Ossenkoppele (VU University Medical Center Amsterdam, The Netherlands)
Immunetherapy in AML: Form AlloSCT Towards CARt Cell Therapy: Marion Subklewe (Ludwig Maximilian University, Deutschland)  
10:00-10:30 COFFEE BREAK
10:30-12:00 ACUTE LYMPHOBLASTIC LEUKEMIA
Scientific Chair: Dieter Hoelzer (University of Frankfurt, Germany)
12:00-14:00 SATELLITE SYMPOSIUM/ LUNCH
14:00-15:30 CHRONIC MYELOID LEUKEMIA
Scientific Chair: Jane Apperley (Imperial College London, UK)
15:30-16:00 COFFEE BREAK
16:00-17:30 MULTIPLE MYELOMA
Scientific Chair: Pieter Sonneveld (Erasmus MC, The Netherlands)
17:30-17:45 COFFEE BREAK
17:45-18:45 MEETING THE CHALLENGE OF EMERGING PATHOGENS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: ADVANCES IN DIAGNOSIS, TREATMENT, AND PREVENTION
Scientific Chair: TBA
19:00-19:30 WELCOME RECEPTION 

 

TIME MAY 4, 2019
08:30-10:00 CHRONIC LYMPHOCYTIC LEUKEMIA
Scientific Chair: TBA
10:00-10:30 COFFEE BREAK
10:30-12:00 HODGKIN LYMPHOMA
Scientific Chair: Andreas Engert (University Hospital of Cologne, Germany)
 1st line treatment of HL : Andreas Engert (University Hospital of Cologne, Germany) 
 NLPHL: Dennis Eichenauer (University of Cologne, Germany)
Recent Developments in Relapsed/Refractory cHL: Paul Bröckelmann (University of Cologne, Germany)
12:00-14:00 SATELLITE SYMPOSIUM/ LUNCH
14:00-15:00 INDOLENT LYMPHOMAS
Scientific Chair: Eva Kimby (Karolinska Institute, Sweeden)
Novelties in the Management of Marginal Zone Lymphoma: Catherine Thieblemont (Hospital Saint Louis,Paris)
Cellular Therapies for Follicular Lymphoma: Koen Van Besien (Presbyterian Hospital, Newyork)
Follicular Lymphoma – Focus on Therapy: Eva Kimby (Karolinska Institute, Sweeden)
15:00-16:00 COFFEE BREAK
16:00-17:30 AGGRESSIVE LYMPHOMAS
Scientific Chair: Martin Dreyling (Klinikum der Universität LMU München, Germany)
Current Standards in First Line DLBCL: Andrew Davies (University of Southampton, UK)
Molecular Subtypes of DLBCL and Clinical Implications: Björn Chapui (University Medical Center, Germany)
Mantle Cell Lymphoma: Current Standards and Future Study Concepts: Martin Dreyling (Klinikum der Universität LMU München, Germany)